Why is ACRV down?
Down 49% in a year while the S&P 500 rose 7%.
- Its $77.8M in cash covers about 5 quarters at the past year's pace;
- Arithmetic on filed figures,
−3Long-term trend
Down 49% in a year while the S&P 500 rose 7%.
−3Long-term trend
Follow ACRV's trial news. Pro members can get an alert when Acrivon Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 13.6% a day with no profit behind it |
| Latest filing | 8-K, Nov 20 |
Expected to report Thu Mar 18, after the close
About 4 quarters
Chief Accounting Officer Katharine Peterson sold 107 shares on Nov 17. 17 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ACRV is #268 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 268 |
Expected to report Thu Mar 18, after the close (in 117 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.42 a share, from $0.47.
“The difference was driven by the timing of clinical trial and related costs for ACR-368 and ACR-2316.”
ACRV's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The difference was primarily driven by employee-related expenses, including stock-based compensation expense.”
From its results filing (SEC filing · Nov 16)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 16, 2026 | -0.7% | -2.0% | not yet |
| Aug 12, 2026 | +0.6% | +7.6% | +39.0% |
| May 13, 2026 | +2.6% | 0.0% | -8.3% |
RSI 27.3, MACD below signal, below both averages. Not scored.
6 insiders sold $46K across 17 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ACRV is 0.0% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
ACRV scores -11 today, which Breakaway calls Poor. It is #268 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 49% in a year while the S&P 500 rose 7%. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ACRV scores -11 today, which Breakaway calls Poor (below zero). That is #268 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ACRV's -11.
6 insiders sold $46K across 17 filings in the last 6 months. No open-market buys on record. The newest is Peter Blume-Jensen, President and CEO, who sold $2K on Nov 17. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.